文献速递乳腺癌

PHERGain-2:HER2阳性早期乳腺癌免化疗病理缓解适应策略

A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.
PubMed 文献 · Ann Oncol · 2026-05-06

PHERGain-2是一项多中心单臂II期研究,评估在HER2阳性早期乳腺癌患者中基于病理完全缓解(pCR)指导的免化疗降阶梯策略。患者接受8周期新辅助曲妥珠单抗-帕妥珠单抗(HP)治疗,术后根据病理反应接受辅助HP或T-DM1。共396例患者入组,pCR率达59.6%,1年健康相关生活质量下降率为42.8%,毒性可预期。

要点

  • HER2阳性早期乳腺癌患者经HP新辅助治疗后pCR率达59.6%。
  • 1年全局健康相关生活质量下降≥10%的患者比例为42.8%。
  • 治疗相关不良事件发生率86.6%,≥3级仅5.6%。

核心结论

  • PHERGain-2显示在HER2阳性早期乳腺癌患者中,基于pCR的免化疗降阶梯策略可保留生活质量,毒性符合HP/T-DM1预期,pCR率与标准化疗联合HP方案相当。

研究设计与样本

  • 多中心、单臂、II期研究,纳入396例初治、中心确认HER2阳性(IHC 3+)、淋巴结阴性、MRI肿瘤5-30 mm的早期乳腺癌成人患者。

主要发现

  • 396例患者中391例(98.7%)接受手术,236例(59.6%)达到pCR(队列A)。
  • 残留病灶患者中148例(37.8%)进入队列B,7例(1.8%)进入队列C。
  • 开始新辅助治疗1年后,全局健康相关生活质量下降≥10%的发生率为42.8%(95%CI 36.9%-48.8%);pCR患者为37.3%(95%CI 30.1%-44.9%),残留病灶患者为51.9%(95%CI 41.9%-61.7%)。
  • 治疗相关不良事件发生率为86.6%(≥3级5.6%),严重不良事件发生率为6.1%。
  • 1例死亡(0.3%)归因于T-DM1相关肺炎。

关键数值与推荐

  • 新辅助治疗:8周期曲妥珠单抗-帕妥珠单抗(负荷剂量H 600 mg + P 1200 mg,维持剂量H 600 mg + P 600 mg)每3周一次;激素受体阳性患者同时接受内分泌治疗。
  • 术后辅助治疗根据病理反应:pCR(ypT0/is ypN0)接受HP(队列A);残留浸润性肿瘤和/或ypN0(i+/mol+)、ypN1mi接受T-DM1 3.6 mg/kg(队列B);ypN1-3接受可选化疗后T-DM1(队列C)。

临床怎么用

  • 对于HER2阳性早期乳腺癌患者,可考虑基于pCR的免化疗降阶梯策略,但需注意该策略仍处于研究阶段。
  • HP双靶向新辅助治疗后可依据病理反应选择辅助HP或T-DM1,避免化疗暴露。

局限性

  • 单臂设计,无随机对照,结论需进一步验证。
  • 随访时间较短,3年无复发生存数据尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PHERGain-2 is a multicenter, single-arm, phase II study evaluating a pathologic complete response (pCR)-guided de-escalation strategy to omit chemotherapy in selected patients with HER2-positive early breast cancer (EBC). PATIENTS AND METHODS: Eligible patients were adults, treatment-naive, centrally confirmed HER2-positive (immunohistochemistry 3+), node-negative EBC, with tumors 5-30 mm by magnetic resonance imaging. Patients received eight cycles of neoadjuvant trastuzumab-pertuzumab (HP) (600 mg H + 1200 mg P loading dose, followed by 600 mg H + 600 mg P maintenance dose) every 3 weeks. Patients with hormone receptor (HR)-positive tumors also received endocrine therapy. After surgery, patients received 10 cycles of adjuvant therapy guided by the pathological response: HP for patients with pCR (ypT0/is ypN0) (cohort A), trastuzumab emtansine (T-DM1; 3.6 mg/kg) for patients with residual invasive breast tumors and/or ypN0(i+/mol+), ypN1mi (cohort B), and optional chemotherapy followed by T-DM1 for patients with ypN1-3 (cohort C). Co-primary endpoints were 1-year health-related quality of life (HRQoL) decline (based on the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire) and 3-year recurrence-free interval (based on the Standardized Definitions for Efficacy End Points). Key secondary endpoints included overall and HR-specific pCR rates and safety. RESULTS: From August 2021 to March 2024, 396 patients initiated neoadjuvant treatment, 391 (98.7%) underwent surgery. A total of 236 patients (59.6%) achieved pCR (cohort A). Among those with residual disease, 148 (37.8%) entered cohort B and 7 (1.8%) cohort C. One year after initiation of neoadjuvant treatment, ≥10% decline rate in global HRQoL was 42.8% [95% confidence interval (CI) 36.9% to 48.8%]; 37.3% (95% CI 30.1% to 44.9%) in patients with pCR and 51.9% (95% CI 41.9% to 61.7%) in those with residual disease. Treatment-related adverse events occurred in 86.6% of patients (5.6% grade ≥3). Serious adverse events occurred in 6.1% of patients. One death (0.3%) due to pneumonitis was attributed to T-DM1. CONCLUSIONS: PHERGain-2 shows meaningful HRQoL preservation, expected HP/T-DM1 toxicity, and an outstanding pCR rate comparable with standard chemotherapy plus HP regimens in this patient population.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Garrigós L, Ruiz-Borrego M, Pérez-García JM, et al. A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study. Ann Oncol. 2026. PMID: 42097893. doi:10.1016/j.annonc.2026.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。